Mutual of America Capital Management LLC Sells 123 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Mutual of America Capital Management LLC lessened its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,798 shares of the medical research company’s stock after selling 123 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Bio-Rad Laboratories were worth $903,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. ING Groep NV bought a new position in Bio-Rad Laboratories in the 3rd quarter valued at $44,000. Banque Cantonale Vaudoise raised its position in Bio-Rad Laboratories by 25.0% in the 3rd quarter. Banque Cantonale Vaudoise now owns 375 shares of the medical research company’s stock valued at $135,000 after purchasing an additional 75 shares during the last quarter. First Eagle Investment Management LLC raised its position in Bio-Rad Laboratories by 139.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 458 shares of the medical research company’s stock valued at $164,000 after purchasing an additional 267 shares during the last quarter. Blue Trust Inc. raised its position in Bio-Rad Laboratories by 42.0% in the 4th quarter. Blue Trust Inc. now owns 480 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 142 shares during the last quarter. Finally, FDx Advisors Inc. bought a new position in Bio-Rad Laboratories in the 3rd quarter valued at $214,000. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Up 0.1 %

Shares of Bio-Rad Laboratories stock opened at $279.91 on Tuesday. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14. Bio-Rad Laboratories, Inc. has a 12 month low of $261.59 and a 12 month high of $473.50. The business has a fifty day simple moving average of $328.92 and a 200 day simple moving average of $319.24. The stock has a market cap of $7.98 billion, a PE ratio of -13.03 and a beta of 0.87.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 15th. The medical research company reported $3.10 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.17. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The business had revenue of $681.18 million during the quarter, compared to analysts’ expectations of $685.00 million. During the same period in the previous year, the firm earned $3.31 earnings per share. The firm’s quarterly revenue was down 6.7% compared to the same quarter last year. Research analysts predict that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on BIO shares. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price objective for the company from $400.00 to $365.00 in a research report on Wednesday, April 3rd. Royal Bank of Canada lowered their target price on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. Finally, UBS Group lifted their target price on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a “buy” rating in a research note on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $468.00.

Insider Buying and Selling

In related news, EVP Michael Crowley sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the completion of the sale, the executive vice president now directly owns 6,942 shares of the company’s stock, valued at $2,332,512. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 17.06% of the stock is owned by insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.